A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

Key Inclusion Criteria: * Patient had to be able to understand and communicate with the investigator and comply with the requirements of the study and had to give a written, signed and dated informed consent before any study assessment was performed. * Male or non-pregnant, non-lactating female patients ≥ 18 years of age. * Clinical diagnosis of active, moderate to severe TED (not sight-threatening) in the study eye at Baseline associated with 2 or more of the following: * Lid retraction \>= 2 mm * Moderate or severe soft tissue involvement * Exophthalmos \>= 3 mm above normal * Inconstant or constant diplopia * Onset of TED symptoms fewer than 12 months prior to Baseline. * CAS \>= 4 (on a 7-point scale, with a score of \>= 3 indicating active TED) in the more severely affected (study) eye at Screening and Baseline. Note: Proptosis is the primary qualifier for selection of the study eye. In case both eyes showed a similar degree of proptosis, other inflammatory signs and symptoms (CAS) were taken into account by the investigator for the selection of the study eye. * Peripheral euthyroidism or mild hypo-/hyperthyroidism defined as free T3 (fT3) and free T4 (fT4) \< 30% above/below normal limits at Screening. Every effort was to be made to correct the mild hypo-/hyperthyroidism promptly and to maintain the euthyroid state until the end of this study. * Orbital MRI assessment available confirming the diagnosis of TED for patients initially presenting with hypo- or eut…